A Phase II Trial of Cabozantinib in Hormone Receptor‐Positive Breast Cancer with Bone Metastases

BACKGROUND: We assessed the antitumor activity of cabozantinib, a potent multireceptor oral tyrosine kinase inhibitor, in patients with hormone receptor‐positive breast cancer with bone metastases. PATIENTS AND METHODS: In this single‐arm multicenter phase II study, patients received an initial star...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jing, Higgins, Michaela J., Tolaney, Sara M., Come, Steven E., Smith, Matthew R., Fornier, Monica, Mahmood, Umar, Baselga, Jose, Yeap, Beow Y., Chabner, Bruce A., Isakoff, Steven J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418363/
https://www.ncbi.nlm.nih.gov/pubmed/32463152
http://dx.doi.org/10.1634/theoncologist.2020-0127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418363/
https://www.ncbi.nlm.nih.gov/pubmed/32463152
http://dx.doi.org/10.1634/theoncologist.2020-0127

Ejemplares similares